Report Company Directory
- Official MFN Executive Order Not as Bad as Feared; Still Plenty of Questions, Though Pharma Tariff Risk Could be Dissipating? by William Blair
- Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 by GlobeNewsWire
- Fast Forward No. 755 by William Blair
- Zealand Pharma announces closing of collaboration and license agreement with Roche by GlobeNewsWire
- Stands to Benefit From Recent Amylin Renaissance and Roche Partnership; December Event to Highlight R&D Initiatives by William Blair
- Morning Notes : ABI BB, ARGX BB, ATEB BB, CPINV BB, SOLB BB, CTPNV NA, ZEAL DC, JDEP NA, MRUS US by KBC Securities
- Zealand Pharma Uneventful 1Q25 results, dapi phase 1 higher dose data in 2Q25 by KBC Securities
- Zealand Pharma - Buy : Q1 report confirms that pipeline and Roche collaboration is on track with cash position after deal close to exceed DKK 17bn - Zealand to host CMD in London on 11 December by Nordea
- Zealand Pharma Announces Financial Results for the First Three Months of 2025 by GlobeNewsWire
- Altimmune Inc "2Q Ph2b MASH readout deserves more attention" (Buy) Merle by UBS AG